Article
Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.
Circulation - 19 May 2009
Mega Jessica L, Close Sandra L, Wiviott Stephen D, Shen Lei, Hockett Richard D, Brandt John T, Walker Joseph R, Antman Elliott M, Macias William L, Braunwald Eugene, Sabatine Marc S
Abstract excerpt
BACKGROUND: Both clopidogrel and prasugrel require biotransformation to active metabolites by cytochrome P450 (CYP) enzymes. Among persons treated with clopidogrel, carriers of reduced-function CYP2C19 alleles have significantly lower levels of active metabolite, diminished platelet inhibition, and higher rates of adverse cardiovascular events. The effect of CYP polymorphisms on the clinical outcomes in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.